Related Experiment Videos
Cyclization-activated prodrugs. Basic esters of 5-bromo-2'-deoxyuridine
W S Saari1, J E Schwering, P A Lyle
1Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Journal of Medicinal Chemistry
|September 1, 1990
Summary
New prodrugs of 5-bromo-2'-deoxyuridine were synthesized. These prodrugs release the active drug via a pH-dependent, non-enzymatic cyclization mechanism, showing potential for controlled drug delivery.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Drug Delivery
Background:
- 5-bromo-2 -deoxyuridine is a nucleoside analog with therapeutic potential.
- Prodrug strategies are crucial for improving drug bioavailability and targeting.
- Understanding drug release mechanisms is key for effective therapeutic design.
Purpose of the Study:
- To synthesize novel 3 ' and 5 '-[[(alkylamino)ethyl]glycyl] esters of 5-bromo-2 -deoxyuridine.
- To evaluate the in vitro stability and drug release characteristics of these novel prodrugs.
- To investigate the mechanism of 5-bromo-2 -deoxyuridine release from the synthesized esters.
Main Methods:
- Synthesis of 5 -bromo-2 -deoxyuridine esters.
- In vitro stability studies at varying pH conditions.
- Analysis of drug release kinetics and structural dependence.
Main Results:
- The synthesized esters demonstrated relative stability at low pH.
- 5-bromo-2 -deoxyuridine was released cleanly from the esters.
- Drug release rates were dependent on pH and the specific structure of the ester.
- The release mechanism was identified as an intramolecular cyclization-elimination reaction, not enzymatic cleavage.
Conclusions:
- The novel basic esters function as cyclization-activated prodrugs.
- This non-enzymatic activation mechanism offers a new approach for prodrug design.
- These prodrugs show promise for controlled release of 5-bromo-2 -deoxyuridine.